FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313377520> ?p ?o ?g. }

• W4313377520 endingPage "154272" @default.
• W4313377520 startingPage "154272" @default.
• W4313377520 abstract "Quinones are naturally or synthetically occurring secondary metabolites that have various bio-dynamics, highlighting their antitumor potential. This has been explored through their selective cytotoxicity, and studies in medicinal chemistry about the relation between biological activity versus chemical structure may lead to the solution of the toxicity problems associated with quinones. In this context, the antitumor effect of a synthetic naphthoquinone, named Ethyl 2-(1,4-Dioxo-1,4-Dihydronaphthalen-2-Ylamino) Acetate, was tested using mice transplanted with Ehrlich ascitic tumor as an experimental model. The acute toxicity test was performed using 30 mice that received the aminoquinone at doses of 100, 200, 300, and 600 mg/kg. After evaluation of the clinical findings in the spontaneous activity tests, the LD50 calculation for the test substance showed low levels of toxicity at doses lower than 244.11 ± 23.29 mg/kg. Thus, three experimental groups were established, where animals transplanted with tumor cells received NaCl vehicle solution (control, n = 6), and the others were treated with 71.7 mg/kg of Methotrexate (n = 6) or 20 mg/kg of Aminoquinone (n = 6). All administrations were intraperitoneal, in a single dose. Three days after the implantation of the tumor cells the animals were weighed daily and evaluated for tumor biometry and development. The treatments occurred five days after the implantation of the tumor cells and were extended for 7 more days. At the end of the 12-day experimental period, all animals were euthanized for biochemical and histopathological analyses of the tumors and vital organs. The spontaneous activity test showed that the amount of responses associated with the nervous system tends to increase with the increase in dosage, highlighting the excitatory effect on the central nervous system in almost all dosages employed, followed by depressant activities on this system. There was a significant tumor reduction, both in animals treated with methotrexate (71.7 %) and in those treated with aminoquinone (91.6 %) in the control group. There was no significant difference in tumor volume between the animals treated with aminoquinone or methotrexate. The histopathological analysis revealed that in both treatments there were fewer mitoses in the tumor mass compared to the control group. However, there was apparent toxicity to the liver, heart, and left kidney in the treatment with methotrexate compared to aminoquinone. The significant capacity for tumor reduction presented by aminoquinone allows pointing it as a promising alternative for the development of a more efficient drug to control tumor development, being necessary for the development of new studies to deepen the knowledge about its mechanisms of action." @default.
• W4313377520 created "2023-01-06" @default.
• W4313377520 creator A5015589655 @default.
• W4313377520 creator A5026991947 @default.
• W4313377520 creator A5032295752 @default.
• W4313377520 creator A5043101422 @default.
• W4313377520 creator A5051461371 @default.
• W4313377520 creator A5052254592 @default.
• W4313377520 creator A5058980125 @default.
• W4313377520 creator A5072000554 @default.
• W4313377520 creator A5078335743 @default.
• W4313377520 creator A5089878578 @default.
• W4313377520 date "2023-01-01" @default.
• W4313377520 modified "2023-10-01" @default.
• W4313377520 title "Role of synthetical amynoquinone ethyl 2-(1,4-dioxo-1,4-dihydronaphthalen-2-ylamino) acetate in inhibition of Ehrlich’s tumor" @default.
• W4313377520 cites W1627796459 @default.
• W4313377520 cites W1971242881 @default.
• W4313377520 cites W1973629782 @default.
• W4313377520 cites W1986594578 @default.
• W4313377520 cites W1989999044 @default.
• W4313377520 cites W1997126087 @default.
• W4313377520 cites W2002487999 @default.
• W4313377520 cites W2009575006 @default.
• W4313377520 cites W2015938399 @default.
• W4313377520 cites W2017092772 @default.
• W4313377520 cites W2020224334 @default.
• W4313377520 cites W2024049900 @default.
• W4313377520 cites W2037140439 @default.
• W4313377520 cites W2042291247 @default.
• W4313377520 cites W2053516011 @default.
• W4313377520 cites W2055505306 @default.
• W4313377520 cites W2090990681 @default.
• W4313377520 cites W2094419555 @default.
• W4313377520 cites W2145180842 @default.
• W4313377520 cites W2156778829 @default.
• W4313377520 cites W2163571511 @default.
• W4313377520 cites W2171262207 @default.
• W4313377520 cites W2304197667 @default.
• W4313377520 cites W2343786611 @default.
• W4313377520 cites W2364200298 @default.
• W4313377520 cites W2520903395 @default.
• W4313377520 cites W2768512861 @default.
• W4313377520 cites W2791100060 @default.
• W4313377520 cites W2794839975 @default.
• W4313377520 cites W2795391805 @default.
• W4313377520 cites W2810065091 @default.
• W4313377520 cites W2810166530 @default.
• W4313377520 cites W2891486519 @default.
• W4313377520 cites W2955729565 @default.
• W4313377520 cites W3096301009 @default.
• W4313377520 cites W3125784837 @default.
• W4313377520 cites W3148418956 @default.
• W4313377520 cites W3200635930 @default.
• W4313377520 cites W3203649017 @default.
• W4313377520 cites W4231592223 @default.
• W4313377520 cites W4233729049 @default.
• W4313377520 doi "https://doi.org/10.1016/j.prp.2022.154272" @default.
• W4313377520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36525850" @default.
• W4313377520 hasPublicationYear "2023" @default.
• W4313377520 type Work @default.
• W4313377520 citedByCount "0" @default.
• W4313377520 crossrefType "journal-article" @default.
• W4313377520 hasAuthorship W4313377520A5015589655 @default.
• W4313377520 hasAuthorship W4313377520A5026991947 @default.
• W4313377520 hasAuthorship W4313377520A5032295752 @default.
• W4313377520 hasAuthorship W4313377520A5043101422 @default.
• W4313377520 hasAuthorship W4313377520A5051461371 @default.
• W4313377520 hasAuthorship W4313377520A5052254592 @default.
• W4313377520 hasAuthorship W4313377520A5058980125 @default.
• W4313377520 hasAuthorship W4313377520A5072000554 @default.
• W4313377520 hasAuthorship W4313377520A5078335743 @default.
• W4313377520 hasAuthorship W4313377520A5089878578 @default.
• W4313377520 hasConcept C109316439 @default.
• W4313377520 hasConcept C116263406 @default.
• W4313377520 hasConcept C126322002 @default.
• W4313377520 hasConcept C150903083 @default.
• W4313377520 hasConcept C151730666 @default.
• W4313377520 hasConcept C178790620 @default.
• W4313377520 hasConcept C185592680 @default.
• W4313377520 hasConcept C202751555 @default.
• W4313377520 hasConcept C207001950 @default.
• W4313377520 hasConcept C2779343474 @default.
• W4313377520 hasConcept C2781059491 @default.
• W4313377520 hasConcept C29730261 @default.
• W4313377520 hasConcept C33070731 @default.
• W4313377520 hasConcept C55493867 @default.
• W4313377520 hasConcept C71924100 @default.
• W4313377520 hasConcept C86803240 @default.
• W4313377520 hasConcept C98274493 @default.
• W4313377520 hasConceptScore W4313377520C109316439 @default.
• W4313377520 hasConceptScore W4313377520C116263406 @default.
• W4313377520 hasConceptScore W4313377520C126322002 @default.
• W4313377520 hasConceptScore W4313377520C150903083 @default.
• W4313377520 hasConceptScore W4313377520C151730666 @default.
• W4313377520 hasConceptScore W4313377520C178790620 @default.
• W4313377520 hasConceptScore W4313377520C185592680 @default.
• W4313377520 hasConceptScore W4313377520C202751555 @default.
• W4313377520 hasConceptScore W4313377520C207001950 @default.

• next